Finance

Lists
Q2 2026 earnings • released • EPS miss -20.56% • Revenue beat +0.12%
See results
OGN:NYSE
Organon & Co
$13.56
0.00%
(0.00) 1D
Aug 4, 1:37:08 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for OGN...
Open
$13.57
High
$13.57
Low
$13.55
Mkt. cap
3.56B
Avg. vol.
2.48M
Volume
498.22K
Dividend
0.59%
Quarterly dividend
$0.02
Ex-dividend date
Aug 14, 2026
P/E ratio
17.38
52-wk high
$13.60
52-wk low
$5.69
EPS
$0.78
Beta
1.55
Shares outstanding
262.61M
No. of employees
10K
Open
$13.57
High
$13.57
Low
$13.55
Mkt. cap
3.56B
Avg. vol.
2.48M
Volume
498.22K
Dividend
0.59%
Quarterly dividend
$0.02
Ex-dividend date
Aug 14, 2026
P/E ratio
17.38
52-wk high
$13.60
52-wk low
$5.69
EPS
$0.78
Beta
1.55
Shares outstanding
262.61M
No. of employees
10K
News stories
From sources across the web
Profile
Organon & Co. is an American pharmaceutical company originally founded in Oss, The Netherlands and now headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy, and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States. Wikipedia
About Organon & Co
CEO-
Employees10K
Founded1923
HeadquartersJersey City, New Jersey, United States
SectorPharmaceutical industry
Websiteorganon.com
Analyst
Recommendation
Action
Price target
Projected
Date
Navann Ty
Exane BNP Paribas
Hold
Downgraded
$14.00
+3.2%
04/28/2026
David Amsellem
Piper Sandler
Hold
Upgraded
$14.00
+3.2%
04/28/2026
Umer Raffat
Evercore ISI
Hold
Maintained
-
-
04/10/2026
Terence Flynn
Morgan Stanley
Hold
Maintained
$9.00
-33.7%
04/10/2026
Glen Santangelo
Barclays
Sell
Maintained
$8.00
-41%
02/24/2026
Chris Schott
J.P. Morgan
Sell
Maintained
$11.00
-18.9%
02/13/2026
Jason Gerberry
Bank of America Securities
Sell
Maintained
-
-
02/13/2026
Last report
Jul 31, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.85 / $1.07
-20.56%miss
Revenue / Est. (USD)
1.56B / 1.56B
+0.12%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
1.60B
1.51B
1.46B
1.56B
Cost of goods sold
733.00M
741.00M
670.00M
711.00M
Cost of revenue
733.00M
741.00M
670.00M
711.00M
Research and development expenses
84.00M
91.00M
93.00M
90.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
415.00M
431.00M
424.00M
434.00M
Operating expense
499.00M
522.00M
517.00M
524.00M
Total operating expenses
1.23B
1.26B
1.19B
1.24B
Operating income
370.00M
244.00M
273.00M
323.00M
Other non operating income
30.00M
-18.00M
15.00M
-3.00M
EBT including unusual items
243.00M
-148.00M
213.00M
183.00M
EBT excluding unusual items
255.00M
103.00M
170.00M
210.00M
Income tax expense
83.00M
57.00M
67.00M
75.00M
Effective tax rate
34.16%
-38.51%
31.46%
40.98%
Other operating expenses
-
-
-
-
Net income
160.00M
-205.00M
146.00M
108.00M
Net profit margin
9.99%
-13.60%
10.00%
6.93%
Earnings per share
1.01
0.63
0.71
0.85
Interest and investment income
-
-
-
-
Interest expense
-128.00M
-121.00M
-111.00M
-108.00M
Net interest expenses
-128.00M
-121.00M
-111.00M
-108.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
462.00M
340.00M
359.00M
403.00M
Gain or loss from assets sale
-
-
-81.00M
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps